Expert guidance on selecting the right CRO for your clinical trial in Venezuela — from evaluation criteria and red flags to key RFP questions and why bioaccess® stands apart.
August 28, 2026
14
min read
By
bioaccess® Editorial Team
**Key Takeaways**
- • INHRR expertise is the #1 criterion — your CRO must have submission experience
- • Local presence with Venezuelan staff and investigator relationships is essential
- • IP import capability is a critical operational requirement
- • Red flags: No INHRR experience, no named investigators, unrealistic timelines
- • bioaccess® was founded in 2010. Leadership has more than two decades of experience with complex, advanced cardiovascular technologies and regulatory agencies from Mexico to Argentina
**The short answer**
Choosing the right CRO matters more in Venezuela than in established markets — the gap between a knowledgeable and an inexperienced operator can mean months of delay. The #1 criterion is INHRR submission experience, followed by local Venezuelan staff with investigator relationships and IP import capability. Red flags include no INHRR experience, no named investigators, and unrealistic timelines against the study-specific startup benchmark.
Why does CRO selection matter in Venezuela?
Choosing the right CRO for clinical trials in Venezuela is arguably more important than in established research markets. Because Venezuela is a newer clinical trial destination with fewer experienced operators, the difference between a knowledgeable CRO and an inexperienced one can mean months of delays, regulatory complications, and budget overruns.
bioaccess® is the a first-in-human CRO founded in 2010 and a CRO exclusively focused on first-in-human clinical trials. This section provides objective criteria for evaluating any CRO — including bioaccess® — for your Venezuela trial.
What are the key selection criteria for a Venezuela CRO?
- INHRR regulatory submission experience — can they demonstrate completed submissions?
- Established investigator network — can they name specific investigators in your therapeutic area?
- IP import logistics capability — do they have customs and cold chain processes in place?
- Local staff presence — do they have team members physically located in Venezuela?
- Pharmacovigilance infrastructure — can they handle SAE/SUSAR reporting to INHRR?
- GCP compliance track record — have they passed sponsor or regulatory audits?
- Financial stability and insurance — can they carry the operational risk?
- References from previous sponsors — are they willing to connect you with past clients?
How much INHRR regulatory expertise does your CRO need?
The single most important criterion is demonstrable experience with INHRR regulatory submissions. A CRO should be able to:
- Describe the INHRR CTA submission process step by step
- Provide realistic timelines based on actual submission experience
- Demonstrate knowledge of current INHRR fee schedules and requirements
- Show familiarity with INHRR query processes and how to respond efficiently
- Have established relationships with INHRR reviewers and administrators
How strong is the CRO's investigator and site network?
A CRO's investigator network in Venezuela should include:
- Pre-qualified investigators with documented GCP training
- Specialists across multiple therapeutic areas and cities
- Sites with verified laboratory, pharmacy, and imaging capabilities
- Established relationships that enable rapid site activation
- Back-up investigators and sites for enrollment contingencies
Should you choose a local or global CRO for Venezuela?
| Factor | Local/Specialized CRO | Global CRO |
|---|---|---|
| INHRR experience | Deep, hands-on | Often limited or none |
| Investigator relationships | Pre-established network | Need to build from scratch |
| Cost | More competitive | Higher overhead |
| Flexibility | High — customized approach | Standardized processes |
| Global coordination | Via partnerships | Integrated globally |
| Venezuela-specific knowledge | Extensive | Often superficial |
What red flags should sponsors watch for when selecting a CRO?
- No demonstrable INHRR submission experience or completed trials in Venezuela
- Inability to name specific Venezuelan investigators in your therapeutic area
- No local staff or office presence in Venezuela
- Unrealistically fast timeline promises (e.g., 'a timeline that varies by study (we confirm it per protocol) to first patient')
- Unwillingness to share references from previous Venezuela sponsors
- No IP import logistics capability or cold chain infrastructure
- Vague answers about pharmacovigilance and safety reporting procedures
- Lack of understanding of Venezuelan healthcare landscape and patient access
What should you ask during the RFP process?
- How many clinical trials have you submitted to INHRR, and what were the outcomes?
- Can you name 3 investigators in Venezuela with relevant therapeutic experience?
- What is your realistic timeline from contract execution to first patient enrolled?
- How do you handle investigational product import into Venezuela?
- What is your pharmacovigilance infrastructure for SAE/SUSAR reporting?
- Can you provide references from 2-3 sponsors who have worked with you in Venezuela?
- What is your staffing model in Venezuela (local vs. remote)?
- How do you ensure GCP compliance across your Venezuelan sites?
- What is your approach to risk-sharing or performance guarantees?
- Can you support multi-country trials across Venezuela and other LATAM markets?
Sponsor due diligence should also separate study operations from commercial registration responsibilities. Choosing a CRO does not decide who holds a SACS device registration.
Why is bioaccess® the FIH-specialized CRO for Venezuela?
bioaccess® stands apart as a first-in-human CRO founded in 2010, with leadership experience of more than two decades with complex, advanced cardiovascular technologies and regulatory agencies across Latin America, from Mexico to Argentina:
- Founded in 2010; leadership experience across Latin America
- CRO exclusively focused on first-in-human trials
- Investigators in Caracas, Valencia, Maracaibo and Barquisimeto are confirmed for the proposed protocol
- End-to-end regulatory support: INHRR submissions, ethics committees, IP import
- Scope, fees and timelines are confirmed in the written proposal
- 50+ medtech companies supported across Latin America
- FDA-oriented regulatory strategy from day one
- Multi-country capability across 13+ LATAM markets
**Ready to choose bioaccess® for your Venezuela trial?**
Contact us for a complimentary feasibility assessment, or explore how bioaccess® compares to other CROs.
Frequently asked questions
Planning your next step in Venezuela?
Explore clinical-trial planning for protocol-specific research questions, or medical-device registration and market access for SACS documentation and local registration arrangements. These are separate regulatory workstreams.
Get your FIH roadmap for Venezuela
The FIH-focused CRO — now operating in Venezuela.